Considering a median FU of 20 months, the authors reported a median PFS of 12 m (10 m for [177Lu]Lu-PSMA-617-only, 19 m mean PFS for tandem patients) with only one relevant toxicity consisting of G3 anemia and G4 thrombocytopenia in 1 tandem patient treated with 4 cycles of [177Lu]Lu-PSMA-617/I&T plus 2 cycles of [225Ac]Ac-PSMA-I&T. This evidence concerns the gene FOLH1 and Thrombocytopenia.